2024
Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealthPotential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalencePredictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records
Ryuk D, Pelissari D, Alves K, Oliveira P, Castro M, Cohen T, Sanchez M, Menzies N. Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records. BMC Infectious Diseases 2024, 24: 531. PMID: 38802744, PMCID: PMC11129366, DOI: 10.1186/s12879-024-09417-7.Peer-Reviewed Original ResearchConceptsTreatment outcomesFactors associated with unsuccessful treatment outcomesHigher risk of poor treatment outcomeTB treatmentRisk of poor treatment outcomesUnsuccessful treatmentEffectiveness of TB treatmentAssociated with unsuccessful treatmentUnsuccessful treatment outcomesTuberculosis treatment outcomesDrug-susceptible TBHealth system levelMultivariate logistic regression modelService-related factorsTB drug resistanceComorbid health conditionsHealth-related behaviorsCategorizing treatment outcomesPatient-level factorsClinical examination resultsNational Disease Notification SystemPoor treatment outcomesDisease notification systemHIV infectionLogistic regression modelsThe recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova
Chitwood M, Colijn C, Yang C, Crudu V, Ciobanu N, Codreanu A, Kim J, Rancu I, Rhee K, Cohen T, Sobkowiak B. The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova. Nature Communications 2024, 15: 2962. PMID: 38580642, PMCID: PMC10997638, DOI: 10.1038/s41467-024-47282-9.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, Multiple, BacterialGenotypeHumansMoldovaMycobacterium tuberculosisTuberculosis, Multidrug-ResistantConceptsMDR M. tuberculosisGenome sequenceResistance-conferring mutationsBeijing sublineageMDR strainsReproductive fitnessBeijing strainsCulture-positive casesLineagesMtb strainsMultidrug-resistant tuberculosisMDRMtbStrainMDR-TBMutationsResistant tuberculosisMDR-MTBSubstantial riskSublineagesTuberculosisSequenceIdentifying local foci of tuberculosis transmission in Moldova using a spatial multinomial logistic regression model
Lan Y, Crudu V, Ciobanu N, Codreanu A, Chitwood M, Sobkowiak B, Warren J, Cohen T. Identifying local foci of tuberculosis transmission in Moldova using a spatial multinomial logistic regression model. EBioMedicine 2024, 102: 105085. PMID: 38531172, PMCID: PMC10987885, DOI: 10.1016/j.ebiom.2024.105085.Peer-Reviewed Original ResearchConceptsPatterns of spatial aggregationMtb strainsMDR-TBLogistic regression modelsGenome Epidemiology StudySpecific strainsMultidrug-resistant tuberculosisTreated TB casesNational Institute of AllergyMDR phenotypeRegression modelsM. tuberculosisInstitute of AllergyMultinomial logistic regression modelUS National Institutes of HealthNational Institutes of HealthMDR diseasePublic health concernAssociated with local transmissionIncident TBInstitutes of HealthMtbResistant tuberculosisStrainDiagnosing TB
2023
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis
Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L, Knight G, Meghji J, Nguyen L, Rachow A, Schumacher S, Mirzayev F, Cohen T. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nature Communications 2023, 14: 6182. PMID: 37794037, PMCID: PMC10550952, DOI: 10.1038/s41467-023-41937-9.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsGlobal Burden of DiseaseHumansModels, TheoreticalRifampinTuberculosisTuberculosis, Multidrug-ResistantConceptsDisability-adjusted life yearsRifampicin-resistant tuberculosisRR-TBGlobal burdenSubstantial short-term morbidityRifampicin-susceptible tuberculosisShort-term morbidityOverall disease burdenLong-term health impactsPost-treatment careTB survivorsDisease burdenTreatment outcomesTuberculosis survivorsCase detectionLife yearsRifampicin resistanceTuberculosisHealth impactsBurdenHealth expenditureDiseaseSurvivorsMathematical modeling analysisFormer Soviet Union countriesBedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
Sonnenkalb L, Carter J, Spitaleri A, Iqbal Z, Hunt M, Malone K, Utpatel C, Cirillo D, Rodrigues C, Nilgiriwala K, Fowler P, Merker M, Niemann S, Consortium C, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Dreyer V, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grandjean L, Grazian C, Groenheit R, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Khot R, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Mansjö M, Matias D, Meintjes G, de Freitas Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Musser K, Ngcamu D, Hoang N, Niemann S, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Rodger G, Rodrigues C, Rodwell T, Roohi E, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker S, Warren R, Werngren J, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Yu X, Yang Y, Zhao Y, Yao S, Zhu B. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. The Lancet Microbe 2023, 4: e358-e368. PMID: 37003285, PMCID: PMC10156607, DOI: 10.1016/s2666-5247(23)00002-2.Peer-Reviewed Original ResearchConceptsMutation catalogueIn silico data analysisBedaquiline resistanceClofazimine resistanceResistance mechanismsProtein modelsClinical Mycobacterium tuberculosis complex isolatesImpaired DNA bindingClinically resistant strainsMinimum inhibitory concentrationVariants in vitroPacBio sequencingGenome sequenceGenomic rearrangementsGenomic variantsIn vitroExperimental evolutionGenotype dataTranscriptional repressorDrug resistance mechanismsClinical isolatesPhenotypic dataResistance determinantsDNA bindingProtein dimerisation
2022
Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania
Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, Minde J, Chisonjela F, Cohen T, Menzies NA. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. The Lancet Global Health 2022, 10: e1646-e1654. PMID: 36240830, PMCID: PMC9553191, DOI: 10.1016/s2214-109x(22)00372-2.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsCD4 Lymphocyte CountCost-Benefit AnalysisHIV InfectionsHumansIsoniazidTanzaniaTuberculosisConceptsIsoniazid preventive therapyCD4 cell countAntiretroviral therapyCell countART cohortAverage CD4 cell countHigher CD4 cell countsLarge HIV treatment programHealth impactsTuberculosis preventive treatmentHIV treatment programsLifetime costsIncremental lifetime costLifetime health benefitsCourse of infectionGreater health gainsLong-term healthART initiationTreat guidelinesHIV cohortPreventive therapyTuberculosis riskUS National InstitutesHIV programsSubgroup analysisNational survey in South Africa reveals high tuberculosis prevalence among previously treated people
Marx FM, Hesseling AC, Martinson N, Theron G, Cohen T. National survey in South Africa reveals high tuberculosis prevalence among previously treated people. The Lancet Infectious Diseases 2022, 22: 1273. PMID: 36029778, DOI: 10.1016/s1473-3099(22)00494-7.Peer-Reviewed Original ResearchA crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates
Fowler P, Wright C, Spiers H, Zhu T, Baeten E, Hoosdally S, Cruz A, Roohi A, Kouchaki S, Walker T, Peto T, Miller G, Lintott C, Clifton D, Crook D, Walker A, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grazian C, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Matias D, Meintjes G, Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Dreyer V, Chetty D, Musser K, Ngcamu D, Nhung H, Grandjean L, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Robinson E, Rodger G, Rodrigues C, Rodwell T, Roohi A, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Steyn A, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker A, Warren R, Werngren J, Groenheit R, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Xiao Y, Yang Y, Yanlin Z, Yao S, Zhu B, Niemann S, O'Donnell M. A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates. ELife 2022, 11: e75046. PMID: 35588296, PMCID: PMC9286738, DOI: 10.7554/elife.75046.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsHumansMicrobial Sensitivity TestsMycobacterium tuberculosisTuberculosisVolunteersConceptsMinimum inhibitory concentrationIncreasing prevalence of resistanceBroth microdilution platesAntibiotic susceptibility testingPrevalence of resistanceInhibitory concentrationPanel of antibioticsClinical samplesSusceptibility testingMicrodilution platesDilution platingTreatment outcomesIncreased prevalenceAntitubercular drugsAntibioticsInhibited growthDrugCitizen science platformRespiratory diseaseLaboratory scientistsVolunteersPre-determined concentrationsThe 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
Walker T, Miotto P, Köser C, Fowler P, Knaggs J, Iqbal Z, Hunt M, Chindelevitch L, Farhat M, Cirillo D, Comas I, Posey J, Omar S, Peto T, Suresh A, Uplekar S, Laurent S, Colman R, Nathanson C, Zignol M, Walker A, Crook D, Ismail N, Rodwell T, Consortium T, Walker A, Steyn A, Lalvani A, Baulard A, Christoffels A, Mendoza-Ticona A, Trovato A, Skrahina A, Lachapelle A, Brankin A, Piatek A, Cruz A, Koch A, Cabibbe A, Spitaleri A, Brandao A, Chaiprasert A, Suresh A, Barbova A, Van Rie A, Ghodousi A, Bainomugisa A, Mandal A, Roohi A, Javid B, Zhu B, Letcher B, Rodrigues C, Nimmo C, NATHANSON C, Duncan C, Coulter C, Utpatel C, Liu C, Grazian C, Kong C, Köser C, Wilson D, Cirillo D, Matias D, Jorgensen D, Zimenkov D, Chetty D, Moore D, Clifton D, Crook D, van Soolingen D, Liu D, Kohlerschmidt D, Barreira D, Ngcamu D, Lazaro E, Kelly E, Borroni E, Roycroft E, Andre E, Böttger E, Robinson E, Menardo F, Mendes F, Jamieson F, Coll F, Gao G, Kasule G, Rossolini G, Rodger G, Smith E, Meintjes G, Thwaites G, Hoffmann H, Albert H, Cox H, Laurenson I, Comas I, Arandjelovic I, Barilar I, Robledo J, Millard J, Johnston J, Posey J, Andrews J, Knaggs J, Gardy J, Guthrie J, Taylor J, Werngren J, Metcalfe J, Coronel J, Shea J, Carter J, Pinhata J, Kus J, Todt K, Holt K, Nilgiriwala K, Ghisi K, Malone K, Faksri K, Musser K, Joseph L, Rigouts L, Chindelevitch L, Jarrett L, Grandjean L, Ferrazoli L, Rodrigues M, Farhat M, Schito M, Fitzgibbon M, Loembé M, Wijkander M, Ballif M, Rabodoarivelo M, Mihalic M, WILCOX M, Hunt M, ZIGNOL M, Merker M, Egger M, O'Donnell M, Caws M, Wu M, Whitfield M, Inouye M, Mansjö M, Thi M, Joloba M, Kamal S, Okozi N, ISMAIL N, Mistry N, Hoang N, Rakotosamimanana N, Paton N, Rancoita P, Miotto P, Lapierre P, Hall P, Tang P, Claxton P, Wintringer P, Keller P, Thai P, Fowler P, Supply P, Srilohasin P, Suriyaphol P, Rathod P, Kambli P, Groenheit R, Colman R, Ong R, Warren R, Wilkinson R, Diel R, Oliveira R, Khot R, Jou R, Tahseen S, Laurent S, Gharbia S, Kouchaki S, Shah S, Plesnik S, Earle S, Dunstan S, Hoosdally S, Mitarai S, Gagneux S, Omar S, Yao S, Lapierre S, Battaglia S, Niemann S, Pandey S, Uplekar S, Halse T, Cohen T, Cortes T, Prammananan T, Kohl T, Thuong N, Teo T, Peto T, Rodwell T, William T, Walker T, Rogers T, Surve U, Mathys V, Furió V, Cook V, Vijay S, Escuyer V, Dreyer V, Sintchenko V, Saphonn V, Solano W, Lin W, van Gemert W, He W, Yang Y, Zhao Y, Qin Y, Xiao Y, Hasan Z, Iqbal Z, Puyen Z. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. The Lancet Microbe 2022, 3: e265-e273. PMID: 35373160, PMCID: PMC7612554, DOI: 10.1016/s2666-5247(21)00301-3.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug ResistanceEthambutolMicrobial Sensitivity TestsMutationMycobacterium tuberculosisWorld Health OrganizationConceptsConsistent with susceptibilityAssociated with resistancePhenotypic resistanceDrug susceptibility testingSusceptibility testingPositive predictive valueAssociated with phenotypic resistanceWhole-genome sequencingPrevalence of phenotypic resistanceMolecular diagnosticsDrug susceptibility testing dataUniversal drug susceptibility testingMutations associated with drug resistanceOdds ratioSusceptibility testing dataDrug resistance predictionImplementation of molecular diagnosticsBinary phenotypesPredictive valueGene approachMTBC isolatesUnique mutationsFisher's exact testAnti-tuberculosis drugsGenotype analysisPhylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, Chitwood MH, Alexandru S, Bivol S, Russi M, Havumaki J, Cudahy P, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Menzies NA, Warren JL, Crudu V, Colijn C, Cohen T. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLOS Medicine 2022, 19: e1003933. PMID: 35192619, PMCID: PMC8903246, DOI: 10.1371/journal.pmed.1003933.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisDrug-resistant M. tuberculosisM. tuberculosis strainsPutative transmission clustersM. tuberculosisTransmission clustersMultidrug-resistant M. tuberculosis strainsTuberculosis strainsMultiple M. tuberculosis strainsCulture-positive TB casesLocal transmissionMDR-TB epidemicDrug-susceptible tuberculosisDrug resistance mutationsDrug resistance profilesUrgency of interventionTB casesDemographic dataNew casesTuberculosisInadequate treatmentNatural historyResistance mutationsBeijing lineageMycobacterium tuberculosis
2021
Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting
Cates L, Crudu V, Codreanu A, Ciobanu N, Fosburgh H, Cohen T, Menzies N. Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting. The International Journal Of Tuberculosis And Lung Disease 2021, 25: 228-230. PMID: 33688812, PMCID: PMC7948759, DOI: 10.5588/ijtld.20.0586.Peer-Reviewed Original Research
2020
Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi.
Hsieh YL, Jahn A, Menzies NA, Yaesoubi R, Salomon JA, Girma B, Gunde L, Eaton JW, Auld A, Odo M, Kiyiika CN, Kalua T, Chiwandira B, Mpunga JU, Mbendra K, Corbett L, Hosseinipour MC, Cohen T, Kunkel A. Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 643-650. PMID: 33177475, PMCID: PMC8564780, DOI: 10.1097/qai.0000000000002497.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsDrug Administration ScheduleHIV InfectionsHumansIncidenceIsoniazidMalawiTuberculosis, PulmonaryConceptsIsoniazid preventive therapyIPT programIPT strategyPreventive therapyContinuous isoniazid preventive therapyMore TB casesHIV-positive adultsCases of tuberculosisAnticipated health effectsComparable health benefitsHIV/AIDSCause deathAntiretroviral therapyTB casesTB controlTB incidenceDrug costsMalawi MinistryMean reductionTuberculosisMycobacterium tuberculosisTherapyAnticipated health impactsHealth effectsHealth benefitsRisk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study
Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases 2020, 20: 789. PMID: 33097000, PMCID: PMC7585300, DOI: 10.1186/s12879-020-05515-4.Peer-Reviewed Original ResearchConceptsM. tuberculosis infectionRecurrent tuberculosisSuccessful treatmentTuberculosis recurrenceHazard ratioSmear gradeTuberculosis infectionRisk factorsSmear-positive pulmonary tuberculosisCox proportional hazards modelSputum smear gradeRepetitive unit-variable number tandem repeat (MIRU-VNTR) typingHigh-burden settingsRisk of recurrenceProportional hazards modelSuccessful treatment completionRecurrent diseaseCohort studyPulmonary tuberculosisBurden settingsClinical presentationRecurrent episodesInitial episodeNumber tandem repeat typingTreatment completionOngoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children versus adults
McQuaid CF, Cohen T, Dean AS, Houben RMGJ, Knight GM, Zignol M, White RG. Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children versus adults. European Respiratory Journal 2020, 57: 2002504. PMID: 32855219, DOI: 10.1183/13993003.02504-2020.Peer-Reviewed Original ResearchConceptsMDR/RR-TBRR-TBOdds ratioPediatric TB casesGlobal TB epidemicRifampicin-resistant tuberculosisPopulation-representative surveyTB casesBurden countriesTB epidemicMost settingsTuberculosisDrug resistanceTransmission riskCountry-specific estimatesAdultsChildrenAgeFurther investigationMultidrugOddsFormer Soviet Union countriesSufficient dataSettingSoviet Union countries
2019
Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study
Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. The BMJ 2019, 367: l5894. PMID: 31649017, PMCID: PMC6812583, DOI: 10.1136/bmj.l5894.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntitubercular AgentsChildChild, PreschoolContact TracingDisease ProgressionFemaleFollow-Up StudiesHumansIncidenceInfantInfant, NewbornIsoniazidKaplan-Meier EstimateMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPeruProspective StudiesRifampinSputumTuberculin TestTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryYoung AdultConceptsDrug-sensitive tuberculosisMultidrug-resistant tuberculosisHousehold contactsProspective cohort studySensitive tuberculosisTuberculosis infectionResistant tuberculosisCohort studyTuberculosis diseaseHigh riskDrug-resistant Mycobacterium tuberculosisIncident tuberculosis diseasePhenotypic drug resistanceDistrict Health CenterResistant Mycobacterium tuberculosisDrug-susceptible strainsDrug resistance profilesActive diseasePulmonary tuberculosisDisease progressionGuideline producersHealth centersIndex patientsEffective treatmentPatientsNotification of relapse and other previously treated tuberculosis in the 52 health districts of South Africa
Marx F, Cohen T, Lombard C, Hesseling A, Dlamini S, Beyers N, Naidoo P. Notification of relapse and other previously treated tuberculosis in the 52 health districts of South Africa. The International Journal Of Tuberculosis And Lung Disease 2019, 23: 891-899. PMID: 31533878, DOI: 10.5588/ijtld.18.0609.Peer-Reviewed Original ResearchConceptsSouth African health districtTB casesCase notification ratesHealth districtTB burdenNotification ratesHigh case notification ratesHIV co-infection rateHuman immunodeficiency virus (HIV) prevalenceTB case notification ratesAntenatal HIV prevalenceSecondary preventive therapyDrug-susceptible tuberculosisNew TB casesCo-infection rateTreatment history informationPreventive therapyMultivariable analysisHIV prevalenceSouth African districtPatient categoriesRelapseTuberculosisTreatment monitoringVirus prevalence
2018
Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogenPan-tuberculosis regimens: an argument for
Wallis RS, Cohen T, Menzies NA, Churchyard G. Pan-tuberculosis regimens: an argument for. The Lancet Respiratory Medicine 2018, 6: 239-240. PMID: 29595501, DOI: 10.1016/s2213-2600(18)30096-1.Peer-Reviewed Original Research